Stockscreener 앱 받기
146.47
0.62%
-0.92
시간 외 거래:
145.70
-0.77
-0.53%
전일 마감가:
$147.39
열려 있는:
$145.64
하루 거래량:
5.51M
Relative Volume:
3.76
시가총액:
$21.34B
수익:
$9.61B
순이익/손실:
$1.62B
주가수익비율:
7.9733
EPS:
18.37
순현금흐름:
$1.77B
1주 성능:
-2.37%
1개월 성능:
-6.11%
6개월 성능:
-35.07%
1년 성능:
-40.98%
1일 변동 폭
$145.07
$147.85
1주일 범위
$145.07
$154.24
52주 변동 폭
$145.07
$268.30
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
146.47 | 21.34B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen (NASDAQ:BIIB) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - MSN
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Biogen in talks to move to MIT's Volpe development, sources say - NBC Boston
Biogen (NASDAQ:BIIB) Downgraded to Market Perform Rating by BMO Capital Markets - MarketBeat
Biogen stock under pressure as rare disease growth lags, says BMO - Investing.com
Neuroimmunology Drugs Market Key Players AnalysisAB Science - openPR
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Recombinant DNA Technology Market Expected to Reach Huge Growth - openPR
Biogen (NASDAQ:BIIB) Sets New 52-Week LowHere's Why - MarketBeat
Coagulation Factor Deficiency Market Key Players AnalysisPfizer Inc, Grifols, Biogen, Octapharma, Baxter. - openPR
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Eli Lilly's Alzheimer's treatment approved in China - Reuters
Eli Lilly's Alzheimer's treatment approved in China (Dec. 17) - Yahoo Canada Finance
Biogen's SWOT analysis: stock outlook amid alzheimer's drug launch and pipeline shifts - Investing.com
Multiple Sclerosis Therapeutics Market to See Booming Growth - openPR
Gene Therapy Market Key Players AnalysisNovartis Ag, Biogen - openPR
Biogen Stock: Is BIIB Underperforming the Healthcare Sector? - Nasdaq
Biogen Stock: Is BIIB Underperforming The Healthcare Sector? - Barchart
Why are Biogen, Pfizer, and GSK Trading at a Discount? - Baystreet.ca
Franklin Resources Inc. Sells 13,723 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen downgraded to Hold by Stifelslower progress than expected - Marketscreener.com
Spinal Muscular Atrophy Market Overall Study Report 2024-2031 | - openPR
Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead - MSN
Biogen Inc. stock rises Monday, still underperforms market - MarketWatch
Netflix, Ford, Biogen: Trending tickers - Yahoo Finance
Biogen (NASDAQ:BIIB) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Analyst recommendations: Biogen, Broadcom, Exxon, UnitedHealth, Tesla, Twilio... - Marketscreener.com
World Investment Advisors LLC Acquires Shares of 5,766 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ionis Pharmaceuticals, Inc. announced that it expects to receive $624.972654 million in funding from Biogen Inc. - Marketscreener.com
Quantinno Capital Management LP Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Hits New 12-Month LowShould You Sell? - MarketBeat
Oddo BHF Asset Management Sas Purchases Shares of 7,136 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval - Citeline
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug - BioPharma Dive
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Inspire Trust Co. N.A. - MarketBeat
Biogen ALS drug needs to be covered by MA plans, CMS says - MSN
Private Medicare plans must cover Biogen's ALS drug, US agency says - Reuters
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Kidney Disease - Biogen
Biogen's SWOT analysis: stock faces leqembi launch hurdles amid pipeline shifts - Investing.com
Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
Saratoga Research & Investment Management Sells 7,071 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Virtu Financial LLC Invests $4.11 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The Escalator: Biogen, Accent Therapeutics, Xira Therapeutics and more - MM+M Online
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Geode Capital Management LLC - MarketBeat
Public Employees Retirement System of Ohio Has $10.26 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Nomura Asset Management Co. Ltd. Has $9.56 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Postpartum Depression Treatment Market Size, Trends, Growth, - openPR
Biogen Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.83%
1.48%
자본화:
|
볼륨(24시간):